Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

Pediatric Infectious Disease Journal

Volumn 16, Issue 10, 1997, Pages 968-974

  Melvin, Ann J ^a,b   Mohan, Kathleen M ^a,b   Manns Arcuino, Laura A ^b   Edelstein, Reva E ^b   Frenkel, Lisa M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Children; Human immunodeficiency virus type 1; Protease inhibitors

Indexed keywords

INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

AGED; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINASE INHIBITION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS RESISTANCE; WEIGHT GAIN;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GROWTH; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; INFANT; VIRAL LOAD;

EID: 0030853709     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199710000-00013     Document Type: Article

References (24)

1. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
2. Stein DS, Fish DG, Bilello JA, Preston JA, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10:485-92.
3. Gulick RM, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC) [Abstract Th. B.931].. Presented at the Eleventh International Conference on AIDS, Vancouver, BC, Canada, July 7 to 12, 1996.
4. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
5. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
6. Mueller BU, Zuckerman J, Nelson RP Jr, et al. Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-538) [Abstract 75-722]. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22 to 26, 1997.
7. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12):1-10.
8. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordan J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
9. Zack JA, Haislip AM, Krogstad P, Chen ISY. Incompletely reverse transcribed human immunodeficiency virus type I genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-25.
10. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
11. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996;2:753-9.
12. Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10:995-9.
13. + lymphocyte parameters in healthy children at risk for infection with the human immunodeficiency virus. Clin Infect Dis 1993;17:123-5.
14. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-6.
15. Schuurman R, Nijhuis M, van-Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
16. Kavlick MF, Shirasaka T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (- -)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Res 1995;28:133-46.
17. Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996;40:527-40.
18. Lacey SF, Larder BA. Novel mutation (V74T) in the human immunodeficiency virus type I reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994;38:1428-32.
19. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr 1980;33:2041-52.
20. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:231-9.
21. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
22. Steigbigel R, Berry P, Teppler H, et al. Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/d), 1000 mg (3.0 g/d) and 800 mg q6h (3.2 g/d) [Abstract Mo. B.412]. Presented at the Eleventh International Conference on AIDS, Vancouver, BC, Canada, July 7 to 12, 1996.
23. Schapiro JM, Winters MA, Vierra M, et al. Causes of long term efficacy and/or drug failure in protease (PR) inhibitor monotherapy [Mo. B.414]. Presented at the Eleventh International Conference on AIDS, Vancouver, BC, Canada, July 7 to 12, 1996.
24. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.